Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXT608 in adults with hypoparathyroidism
NCT06988670Phase 2Recruiting
- Sponsor
- Extend Biosciences
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypoparathyroidism comparing Active (EXT608) with Placebo (2 arms). Primary endpoint: Frequency and severity of treatment emergent adverse events and post-dose change in lab results at 12 weeks. Started May 2025; status: recruiting.
02
Drugs
ext608
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT06988670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988670.